THE WOODLANDS, Texas--(BUSINESS WIRE)--
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company
developing personalized immunotherapies for autoimmune disorders,
including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today
announced that it will hold an Analyst and Investor Event in New York
City, New York on Thursday, October 9, 2021.
Members of Opexa’s senior management team will provide an R&D update and
review of the Company’s Abili-T clinical trial for Secondary Progressive
Multiple Sclerosis and the development program for Neuromyelitis Optica.
The Analyst and Investor Event will take place from 8:00 a.m. to 9:15
a.m. Eastern Time at the New York Hilton Midtown, Madison Room (2nd
floor). If you would like to attend the event, please confirm your
attendance by e-mail to czuckero@opexatherapeutics.com
or via telephone at 281.775.0600.
A live webcast of the event will start at 8:15 a.m. and may be accessed
on the Investor Relations section of the Company’s website, www.opexatherapeutics.com.
An archived version of the webcast will be available for 90 days after
the event on the Company’s website.
About Opexa
Opexa is a biopharmaceutical company developing personalized
immunotherapies with the potential to treat major illnesses, including
multiple sclerosis (MS) as well as other autoimmune diseases such as
neuromyelitis optica (NMO). These therapies are based on Opexa’s
proprietary T-cell technology. The Company’s leading therapy candidate,
Tcelna®, is a personalized T-cell immunotherapy that is in a
Phase IIb clinical development program (the Abili-T trial) for the
treatment of Secondary Progressive MS. Tcelna is derived from T-cells
isolated from the patient’s peripheral blood, expanded ex vivo,
and reintroduced into the patients via subcutaneous injections. This
process triggers a potent immune response against specific subsets of
autoreactive T-cells known to attack myelin. Opexa’s mission is to lead
the field of Precision Immunotherapy® by aligning the
interests of patients, employees and shareholders.
For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com.
Source: Opexa Therapeutics, Inc.